Welcome to our dedicated page for Crinetics Pharmaceuticals SEC filings (Ticker: CRNX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Crinetics Pharmaceuticals's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Crinetics Pharmaceuticals's regulatory disclosures and financial reporting.
Crinetics Pharmaceuticals reported first‑quarter 2026 results that reflect its transition to a commercial-stage company following the U.S. launch of PALSONIFY for acromegaly. Total revenue was $10.7 million, driven by $10.3 million of PALSONIFY net product sales and $0.4 million of collaboration and license revenue.
The company recorded a net loss of $127.8 million as it continued heavy investment in research and development of paltusotine, atumelnant and other endocrine programs, along with commercial and administrative infrastructure. R&D expenses were $100.1 million and selling, general and administrative expenses were $50.8 million.
Crinetics strengthened its balance sheet with a January 2026 underwritten offering of 8.8 million shares, generating approximately $380 million of net proceeds. As of March 31, 2026, cash, cash equivalents and investment securities totaled $1.3 billion, which management believes will fund operations for at least 12 months.
Crinetics Pharmaceuticals reported first-quarter 2026 revenue of $10.7 million, driven by $10.3 million in net product revenue from the U.S. launch of PALSONIFY for acromegaly. Management highlighted strong prescriber uptake, with 232 enrollment forms and 263 unique healthcare providers within the first two quarters of launch, and about 70% of patients on reimbursed therapy.
R&D expenses rose to $100.1 million and selling, general and administrative costs to $50.8 million, reflecting expansion as a commercial-stage company. Net loss widened to $127.8 million. Cash, cash equivalents and investment securities were $1.3 billion, supported by $380 million of net proceeds from a January 2026 equity offering. The company reaffirmed 2026 GAAP operating expense guidance of $600–650 million and non-GAAP operating expense guidance of $480–520 million, and outlined progress on its global PALSONIFY strategy and late-stage pipeline including atumelnant.
CORINUS PHARMACEUTICALS insider sales reported via Form 144: the filing discloses open-market dispositions totaling 120,408 shares across four reported 10b5-1 transactions in March–April 2026. The filing also lists an exercise of 8,985 stock options on 05/04/2026 and 500 RSUs from 03/15/2025.
Vanguard Capital Management reports beneficial ownership of 5,440,646 shares (5.19%) of Crinetics Pharmaceuticals Inc common stock. The filing shows sole dispositive power over 5,440,646 shares and sole voting power for 766,711 shares. The Schedule 13G was signed by Ashley Grim on 04/29/2026.
Crinetics Pharmaceuticals, Inc. filed its Form 10-K reporting operations for the fiscal year ended December 31, 2025. The company is a commercial-stage endocrine-focused biopharma with an FDA-approved product, PALSONIFY (paltusotine), and a diversified pipeline including atumelnant and the NDC candidate CRN09682.
The filing highlights FDA approval of PALSONIFY on September 25, 2025 and U.S. commercial availability in October 2025, ongoing global regulatory activity including a CHMP positive opinion in February 2026, multiple active Phase 1–3 programs, third-party manufacturing and distribution arrangements, and intellectual property estate with patent expirations estimated through the mid-2040s.
Crinetics Pharmaceuticals is holding its 2026 annual shareholder meeting on June 18, 2026 via live webcast. Shareholders of record as of April 20, 2026, when 105,439,535 common shares were outstanding, can vote.
Three Class II directors are up for election, PricewaterhouseCoopers LLP is proposed as the new independent auditor for 2026, and shareholders will cast an advisory “say‑on‑pay” vote on named executive officer compensation. The eight‑member board is majority independent, led by an independent chair, with specialized audit, compensation, nominating, R&D, and commercialization committees. Non‑employee directors receive cash retainers and equity awards under a structured program, and several institutional investors each hold over 7% of the stock.
CRNX filing reports proposed and recent sales of Common Stock by an affiliated holder. The filing lists an exercise of stock options for 20,900 shares on 04/14/2026 (cash exercise) and multiple 10b5-1 sales executed by Jeff Knight: 9,911 shares on 03/16/2026, 85,163 shares on 04/08/2026, and 4,434 shares on 04/13/2026, with cash proceeds shown per trade.
Morgan Stanley Smith Barney LLC reported a Form 144 notice for sale of 4,434 shares of Common Stock of CRNX tied to exercise of stock options on 04/13/2026. The filing also lists prior 10b5-1 sales by Jeff Knight: 85,163 shares on 04/08/2026 and 9,911 shares on 03/16/2026, with proceeds shown in the filing.
Crinetics Pharmaceuticals Chief Dev. & Operating Officer Jeff E. Knight reported an exercise-and-sale transaction in company stock. On April 8, 2026, he exercised stock options to acquire a total of 78,434 shares of Common Stock at exercise prices of $23.98, $20.02, and $19.64 per share.
On the same date, Knight sold 85,163 shares of Common Stock in open market transactions at a volume weighted average price of $40.10 per share, with individual sale prices ranging from $40.00 to $40.34. The sale was executed automatically under a pre-arranged Rule 10b5-1 trading plan. After these transactions, he directly holds 105,289 shares of Crinetics common stock.
Crinetics Pharmaceuticals, Inc. reports that Jeff Knight’s previously disclosed resignation as Chief Development and Operating Officer became effective on April 10, 2026. On that date, the company and Mr. Knight entered into an Independent Consultant Agreement covering operational and clinical development services.
The consulting term runs from April 10, 2026 to April 10, 2027, with an option to renew for six months if both sides agree in writing. Mr. Knight will be paid $400 per hour, up to 20 hours per month, plus reimbursement of reasonable pre-approved expenses. His unvested restricted stock units and stock options are forfeited on the resignation date, while vested options remain exercisable for three months after the consulting period ends or earlier termination for cause. He also provides a general release of claims, and the company extends certain indemnification rights during the consulting term.